Xtime said it raised $23 million in a deal led by Bessemer Venture Partners and joined by Lumia Capital and existing investors RPM Ventures and Saints Capital. The company said Jeremy Levine, a Bessemer partner, and DFJ Venture Partner Heidi Roizen have joined the board.
You are browsing the archive for Saints Capital - peHUB.
Radius Health Inc. said Tuesday that it closed a $91 million third round of financing. The round includes $66 million in equity financing, and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance for a $25 million multi-draw term loan facility. Five new investors–including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience, and Ipsen Pharma SAS–joined existing investors MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures, and Scottish Widows Investment Partnership in the equity portion of the round. Radius Health is based in Cambridge, Mass. Radius also announced that immediately following the initial closing of the financing, it merged with MPM Acquisition Corp., an unlisted public reporting shell company. The combined company will go by the name Radius Health. Radius is a developer of drug therapies for osteoporosis and women’s health.
Secondary direct investment firm Saints Capital is teaming up with Oxford Bioscience Partners and making an investment in a partnership with Oxford that will make follow on investments in six positions initially owned by Oxford. In conjunction with the transaction, Terry Vance, formerly a Managing Director at EGS Healthcare Capital Partners, is joining Saints as a venture partner to manage certain positions in the new partnership.
AngioScore said Wednesday that it has received $12 million in PE financing led by Saints Capital. Existing institutional investors include Psilos Group Managers, Telegraph Hill Partners, QuestMark Partners, Pelion Venture Partners, California Technology Ventures and Innomed Ventures. Freemont, Calif.-based AngioScore is an endovascular company. Scott Halsted, a Saints Capital MD, was named to AngioScore’s board.
Last summer, Boston Scientific agreed to sell a portfolio of 53 venture capital investments to Saints Capital for approximately $100 million. It was the largest-ever direct secondary sale of healthcare interests, but peHUB has learned that the process was almost derailed by a separate suitor that didn’t have the money to back up its offer.
That bidder was Omega Funds, a healthcare-focused direct secondaries shop with offices in Boston and Switzerland. Kind of ironically, Omega Funds is actually a fundless sponsor, which means that it doesn’t have an existing pool of capital from which to draw. The firm is currently embroiled in a legal tête-à-tête with some of its former employees and advisors – it’s sued them for alleged breaches of noncompete agreements – which is where details of the busted Boston Scientific bid first emerged.
In a response to Omega’s original complaint, defendants Nessan Bermingham and Arthur Rosenthal both submitted affidavits claiming that Omega boss Ottello Stampacchia had claimed that Omega had “oversubscribed” financing commitments to purchase the Boston Scientific direct portfolio (an indirect portfolio of LP interests was sold separately to Paul Capital). They both also say that those representations proved to be false.
Last week, we got word that a Boston-area venture firm was informally shopping one of its hottest portfolio companies to other VC firms. Not shopping the whole thing, mind you, but just the venture firm’s stake. So I called one of the firm’s managing partners, who was understandably cagey in his response.
“We’re always talking to other firms about our companies. Sometimes we call them, and sometimes they call us. And we’re obviously scouring other firms’ portfolios, to see if there’s anything there that we might want to express interest in.”
My point here isn’t to report on the specific situation (still not quite comfortable enough, despite the non-confirmation confirmation), but rather to suggest that venture capital may finally be getting around to recognizing sponsor-to-sponsor sales as a viable exit avenue. It’s what helped buyout firms begin their gold rush earlier this decade, and may be venture’s last best hope for juicing wilted returns.